Regeneron Pharmaceuticals will repurchase about $5 billion of the U.S. drugmaker’s shares directly from France’s Sanofi, without altering their 17-year partnership.
Tianjin, China’s CanSino Biologics entered into a co-development agreement with Vancouver, British Columbia’s Precision NanoSystems for an mRNA lipid nanoparticle vaccine against COVID-19.
AstraZeneca reported plans to manufacture as much as 30 million doses of the University of Oxford’s COVID-19 vaccine for the U.K. market by September 2020, with expectations of 100 million doses by the end of the year.
As the world battles the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2, biopharma and biotech companies are approaching the fight with various weapons – repurposed drugs, antivirals, vaccines and clinical antibodies. One of the companies deeply involved in clinical antibody development against COVID-19 is San Diego-based Sorrento Therapeutics.
Cambridge, Massachusetts-based Dyno Therapeutics came out of stealth mode with an official launch of the company’s proprietary CapsidMap platform.
San Diego-based Sorrento Therapeutics is teaming up with New York City-based Mount Sinai Health System to develop an antibody cocktail called COVI-SHIELD to treat COVID-19.
Mallinckrodt and Massachusetts General Hospital teamed up to evaluate the potential benefits of inhaled nitric oxide as a treatment for pulmonary complications in patients infected with COVID-19.
Deaf-owned software company Wavio announced a strategic partnership with AREA 23, an FCB Health Network Company, which includes a major investment deal for the development and product launch of “See Sound.” Created by AREA 23 and Wavio, the revolutionary home device is scheduled to launch during 2020. The partnership provides the FCB Health Network with company equity in Wavio and revenue share on product sales.
U.S. health agencies, the European drug regulator and 16 top drugmakers will collaborate on vaccine and drug development efforts to fight the coronavirus pandemic, the U.S. National Institutes of Health said.
French healthcare company Sanofi and U.S. start-up technology company Luminostics said they were joining up to work on developing a smartphone-based self-testing solution to see if someone has the COVID-19 coronavirus.
